Zusammenfassung
Die vorliegende Übersicht zum Tumormarker Serotonin wird im Rahmen der Serie „Tumormarker“ des Zentralblatts für Arbeitsmedizin, Arbeitsschutz und Ergonomie publiziert, die sich mit dem immer häufigeren Gebrauch der Bestimmung von spezifischen Markern bei sog. Manager-Vorsorgen und Check-up-Untersuchungen beschäftigt. Serotonin eignet sich grundsätzlich nicht für solche Vorsorgen, sondern ist ein Marker zur Therapie‑, Verlaufs- und Rezidivkontrolle von neuroendokrinen Tumoren. Hier zeigt dieser eine hohe Sensitivität und Spezifität, wobei der Marker aber keinesfalls als Screening-Parameter zur Frühdiagnostik eingesetzt werden soll.
Abstract
The present overview on the tumor marker serotonin is part of the series on tumor markers of the Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie, which deals with the increasing use of the determination of specific markers in so-called manager preventive and check-up examinations. In principle, serotonin is not suitable for such precautionary measures but is a marker for the treatment, progression and recurrence control of neuroendocrine tumors. In this aspect it shows a high sensitivity and specificity but the marker should not be used as a screening parameter for early diagnosis.
Literatur
Gerber A, Jäger M, Groneberg DA (2017) Editorial: Tumormarker in der Vorsorge? Zentralbl Arbeitsmed Arbeitsschutz Ergonomie 67(4):199–200
Tsaur I, Thurn K, Juengel E, Oppermann E, Nelson K, Thomas C, Bartsch G, Oremek GM, Haferkamp A, Rubenwolf P, Blaheta RA (2016) Evaluation of TKLTL1 as a biomarker in serum of prostate cancer patients. Cent European J Urol 69(3):247–251
Zulauf N, Oremek GM, Groneberg D (2016) Bone marker in women with breast cancer. Curr Biomarkers 6:61–68
Onkologie L (2018) S2k-Leitlinie Neuroendokrine Tumoren. Langversion März 2018 AWMF-Register-Nummer: 021/26
Bundesärztekammer (2014) Neufassung der „Richtlinie der Bundesärztekammer zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen – Rili-BÄK“. Dtsch Arztebl 111:A1583–A1618
Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt PM (2015) Validation of new cancer biomarkers: a position statement from the European group on tumor markers. Clin Chem 61(6):809–820
Hölzel D, Schubert-Fritschle G, Schmidt M, Eckel R, Engel J (2016) Klinisch-epidemiologische Krebsregistrierung in Deutschland. Onkologe 22:61–78
In-Vitro-Diagnostika EPURÜ (2009) Richtlinie 98/79/EG des Europäischen Parlaments und des Rates über In-vitro-Diagnostika
Institut RK (2016) Bericht zum Krebsgeschehen in Deutschland 2016 (ICD-10 C15–26)
Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O’Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK (2017) The north American Neuroendocrine Tumor Society Consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas 46(6):707–714
Budnik LT, Adam B, Albin M, Banelli B, Baur X, Belpoggi F, Bolognesi C, Broberg K, Gustavsson P, Göen T, Fischer A, Jarosinska D, Manservisi F, O’Kennedy R, Øvrevik J, Paunovic E, Ritz B, Scheepers PTJ, Schlünssen V, Schwarzenbach H, Schwarze PE, Sheils O, Sigsgaard T, Van Damme K, Casteleyn L (2018) Diagnosis, monitoring and prevention of exposure-related non-communicable diseases in the living and working environment: DiMoPEx-project is designed to determine the impacts of environmental exposure on human health. J Occup Med Toxicol 13:6
Schulte HM, Jacobeit J (2013) Lexikon der Medizinischen Laboratoriumsdiagnostik: Serotonin. Springer, Berlin, Heidelberg
Kunz PL (2015) Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol 33:1855–1863
Bergsland EK (2013) The evolving landscape of neuroendocrine tumors. Semin Oncol 40:4–22
Klimstra DS, Modlin IR, Coppola D et al (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39:707–712
Scherübl H, Streller B, Stabenow R, Herbst H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K, Zappe SM (2013) Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol 19(47):9012–9019
Klöppel G, Perren A, Heitz PU (2004) The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014:13–27
Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossma A, Jense RT, Kulke M, Oeberg K, Rindi G, Sorbye H, Welin S Antibes Consensus Conference Participants (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology 105(3):196–200
Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC (2008) Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev 17(4):959–965
Du Y, Ter-Minassian M, Brais L, Brooks N, Waldron A, Chan JA, Lin X, Kraft P, Christiani DC, Kulke MH (2016) Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study. Endocr Relat Cancer 23(8):587–594
Rinzivillo M, Capurso G, Campana D, Fazio N, Panzuto F, Spada F, Cicchese N, Partelli S, Tomassetti P, Falconi M, Delle Fave G (2016) Risk and protective factors for small intestine neuroendocrine tumors: a prospective case-control study. Neuroendocrinology 103(5):531–537
Jung YS, Yun KE, Chang Y, Ryu S, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Park DI (2014) Risk factors associated with rectal neuroendocrine tumors: a cross-sectional study. Cancer Epidemiol Biomarkers Prev 23(7):1406–1413
Romaniuk А, Lyndin M, Sikora V, Lyndina Y, Romaniuk S, Sikora K (2017) Heavy metals effect on breast cancer progression. J Occup Med Toxicol 12:32
Westermann C, Wendeler D, Nienhaus A (2018) Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents. J Occup Med Toxicol 13:16
Sarrouilhe D, Mesnil M (2018) Serotonin and human cancer: a critical view. Biochimie. https://doi.org/10.1016/j.biochi.2018.06.016
Modlin IM, Bodei L, Kidd M (2016) Neuroendocrine tumor biomarkers: from monoanalytes to transcripts and algorithms. Best Pract Res Clin Endocrinol Metab 30(1):59–77
Sarrouilhe D, Clarhaut J, Defamie N, Mesnil M (2015) Serotonin and cancer: what is the link? Curr Mol Med 15(1):62–77
Joseph L, Gomes MP, Al Solaiman F, John StJ, Ozaki A, Raju M, Dhariwal M, Kim ES (2015) External validation of the HIT Expert Probability (HEP) score. Thromb Haemost 113(3):633–640
Albert PR, Benkelfat C, Descarries L (2012) The neurobiology of depression—revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms. Philos Trans R Soc Lond B Biol Sci 367(1601):2378–2381
Shajib MS, Khan WI (2015) The role of serotonin and its receptors in activation of immune responses and inflammation. Acta Physiol (Oxf) 213(3):561–574
Heinrich E, Trojan L, Friedrich D, Voss M, Weiss C, Michel MS, Grobholz R (2011) Neuroendocrine tumor cells in prostate cancer: evaluation of the neurosecretory products serotonin, bombesin, and gastrin—impact on angiogenesis and clinical follow-up. Prostate 71(16):1752–1758
Fröbe A, Čičin-Šain L, Jones G, Soldič Ž, Lukač J, Bolanča A, Kusič Z (2014) Plasma free serotonin as a marker for early detection of breast cancer recurrence. Anticancer Res 34(3):1167–1169
Abdel-Razik A, Elhelaly R, Elzehery R, El-Diasty A, Abed S, Elhammady D, Tawfik A (2016) Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study. Eur J Gastroenterol Hepatol 28(5):599–605
Baldo BA (2018) Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol 92(8):2457–2473
Cheng S, Tollefson D, He G, Li Y, Guo H, Chai S, Gao F, Gao F, Han G, Ren L, Ren Y, Li J, Wang L, Varma JK, Hu D, Fan H, Zhao F, Bloss E, Wang Y, Rao CY (2018) Evaluating a framework for tuberculosis screening among healthcare workers in clinical settings, Inner Mongolia, China. J Occup Med Toxicol 13:11
Mastrangelo G, Carta A, Arici C, Pavanello S, Porru S (2017) An etiologic prediction model incorporating biomarkers to predict the bladder cancer risk associated with occupational exposure to aromatic amines: a pilot study. J Occup Med Toxicol 12:23
Eisenhawer C, Felten MK, Hager T, Gronostayskiy M, Bruners P, Tannapfel A, Kraus T (2017) Migrating pleural plaque in a patient with asbestos induced pleural disease: a case report. J Occup Med Toxicol 12:25
Fuchs S, Parthier K, Wienke A, Mau W, Klement A (2017) Fostering needs assessment and access to medical rehabilitation for patients with chronic disease and endangered work ability: protocol of a multilevel evaluation on the effectiveness and efficacy of a CME intervention for general practitioners. J Occup Med Toxicol 12:21
Alami YZ, Ghanim BT, Zyoud SH (2018) Epworth sleepiness scale in medical residents: quality of sleep and its relationship to quality of life. J Occup Med Toxicol 13:21
Daba Wami S, Chercos DH, Dessie A, Gizaw Z, Getachew A, Hambisa T, Guadu T, Getachew D, Destaw B (2018) Cotton dust exposure and self-reported respiratory symptoms among textile factory workers in Northwest Ethiopia: a comparative cross-sectional study. J Occup Med Toxicol 13:13
Frohlich MJ, Kroidl RF, Welte T (2018) Oxygen Consumption (V’O2) and physical Strainas measured by the occupational activity of cleaning personnel. J Occup Med Toxicol 13:4
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
K. Passek, N. Zulauf, M.H. Bendels, M. Braun und G.M. Oremek geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Passek, K., Zulauf, N., Bendels, M.H. et al. Der Tumormarker Serotonin. Zbl Arbeitsmed 69, 306–309 (2019). https://doi.org/10.1007/s40664-018-0319-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40664-018-0319-0